Please log in to determine if you are eligible to purchase PT Programs.
CAP/ACMG MOLECULAR GENETICS - MGL2
MGL2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Disease/Gene Challenges per Shipment Number of Shipments
Cystic fibrosis 3 Two shipments per year
DMD/Becker 3
Friedreich ataxia 3
Hemoglobin S/C 3
Huntington 3
Myotonic dystrophy 3
RhD 3
Spinal muscular atrophy 3
Spinocerebellar ataxia 3

Additional Information

  • The cystic fibrosis program modules are designed for laboratories that are testing for the minimum mutation panel for population-based carrier screening (ie, the ACMG-23 mutation panel) from the ACMG Technical Standards and Guidelines for CFTR Mutation Testing, expanded panels, PolyT variant analysis, and/or full gene sequencing.

Program Information

  • Three 50.0‑μg extracted DNA specimens

Shipping Schedule

  • Shipment A: March 25
  • Shipment B: October 15